Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

Equality Impact Assessment (Guidance development) (PDF 178 KB)

Register of interests (PDF 201 KB)

Final draft guidance

Final draft guidance (PDF 339 KB)

Committee papers (PDF 2.16 MB)

Public committee slides (PDF 529 KB)

Committee meeting: 2

Supporting documentation Register of interests (MSWord 44 KB)

Draft guidance

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version) (PDF 337 KB)

Committee papers (PDF 7.24 MB)

Public committee slides (PDF 1.51 MB)

Final scope (PDF 173 KB)

Final stakeholder list (PDF 205 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 145 KB)

Equality impact assessment (Scoping) (PDF 123 KB)

Draft scope post referral (PDF 179 KB)

Draft matrix post referral (PDF 205 KB)

Committee papers (PDF 7.24 MB)

Public committee slides (PDF 1.51 MB)

Draft scope post referral (PDF 337 KB)

Draft matrix post referral (PDF 342 KB)